AVACTA GROUP PLC – Avacta Appoints Patrick Vink Deputy Chairman
RNS Number : 4068L Avacta Group PLC 08 July 2026 Avacta Appoints Healthcare Executive Patrick Vink as Deputy
RNS Number : 4068L Avacta Group PLC 08 July 2026 Avacta Appoints Healthcare Executive Patrick Vink as Deputy
RNS Number : 7341J Avacta Group PLC 25 June 2026 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN
RNS Number : 2872J Avacta Group PLC 23 June 2026 Result of AGM LONDON and PHILADELPHIA
RNS Number : 1791J Avacta Group PLC 22 June 2026 Year-to-date business update ahead of
RNS Number : 7128Z Avacta Group PLC 09 April 2026 Q1 2026 Business Update LONDON
Avacta Group plc (AIM: AVCT) announces that the AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU…
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce its preliminary results for the year ending 31 December 2020.
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the AffiDX® SARS-CoV-2 rapid antigen lateral flow test detects the dominant new variants of the coronavirus, known as the B117, or ‘Kent’, variant, and the D614G variant, as well as the original strain.
Alastair Smith provides overview of pre|CISION™ prodrug technology and update on AVA6000 clinical trial
How a Lateral Flow Rapid Test Works